Navigation Links
Heyltex Corporation to Become Exclusive Distributor of ThyroShield(R)
Date:2/25/2009

Partnership with Fleming Pharmaceuticals to increase access to radiological threat antidote

WASHINGTON, Feb. 25 /PRNewswire-USNewswire/ -- Today, Heyltex Corporation announced an agreement in principle with Fleming Pharmaceuticals for the exclusive distribution of ThyroShield(R) in the United States. ThyroShield(R) Potassium Iodide Oral Solution is a ready-to-use, liquid medicine that protects infants, children, and adults at risk of exposure to radioactive iodine. It is the only FDA-approved liquid potassium iodine product indicated for thyroid protection in a radiation emergency.

By saturating the thyroid gland with potassium iodide, ThyroShield(R) prevents radioactive iodine from being absorbed by the thyroid gland. The product will be available to families through their local pharmacist or online. It is also supplied to the 31 states with commercial nuclear power plants through the Nuclear Regulatory Commission's Program to supply potassium iodide within the 10-mile Emergency Planning Zone and a part of the Department of Health and Human Service's Project BioShield.

"This is an exciting development for Heyltex, as we expand our radiological countermeasure product offerings in the homeland security space," said Alexander Heyl, CEO of Heyltex Corporation. "We're proud that Heyltex is making Americans safer by making ThyroShield(R) available in the event of a radiological attack."

"We are pleased to forge this partnership with Heyltex," said Phill Dritsas, Fleming's President. "This further expands our commitment to ensure that ThyroShield(R) is widely available to meet homeland security needs."

ThyroShield(R) will be the second product addition to the Heyltex portfolio in 2009. Earlier this year, the company began the distribution of Cool Comfort Technology by 32 Degrees(TM) - a new, lightweight, high-absorption cooling fabric that is used in a variety of disaster response and emergency preparedness situations to aid in the temperature moderation of victims and responders.

About Heyltex Corporation

Heyltex Corporation, based in Houston, Texas, was founded in 1979 as a subsidiary of Heyl chemisch-pharmazeutische Fabrik, Berlin Germany. Since 2004, Heyltex has been the exclusive distributor of Radiogardase(R) in the United States. Today, Heyltex is strategically focusing on providing products and solutions to the chemical and pharmaceutical industry. The company is also working to expand the company's product portfolio and market presence by in-licensing, acquiring, and distributing specialty pharmaceuticals, particularly pharmaceutical products related to Homeland Security. Additionally, Heyltex is pursuing opportunities for the distribution of specialty products for the healthcare community. For more information, visit www.heyltex.com.

About Fleming Pharmaceuticals

Fleming Pharmaceuticals, based in Saint Louis County, Missouri, is the manufacturer of the popular OCEAN(R) Premium Saline Nasal Spray, MAGONATE(R) Magnesium Supplement, NEPHROCAPS(R) Softgels, ThyroShield(TM) Potassium Iodide Oral Solution and other specialty prescription and over-the-counter drugs for clinical indications in allergy, pediatrics, nephrology and general nutrition care. For more information, visit www.flemingpharma.com.


'/>"/>
SOURCE Heyltex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding ... The following programs will be expanding due to high demand: Master of Business Administration ... will begin this summer. , School of Business Graduate Program Chair Dr. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study ... severe congenital diaphragmatic hernia have better survival rates if surgery is performed early. ... condition where the diaphragm fails to form completely, letting abdominal organs into the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... patented products, announces the Gyrociser, an exercise invention which aids in proper muscle ... says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery systems, ... PIONEERS 2016 conference, presented by Joseph Gunnar & ... New York . Nadav Kidron , CEO ... Presentation Details:   PIONEERS 2016, ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
Breaking Medicine Technology: